UNDERSTANDING PERIPHERAL NEUROPATHY
WITH ABRAXANE + GEMCITABINE
UNDERSTANDING PERIPHERAL NEUROPATHY WITH ABRAXANE + GEMCITABINE

  • 54% of patients experienced peripheral neuropathy of any grade (227/421)
Peripheral neuropathy with ABRAXANE + gemcitabine Peripheral neuropathy with ABRAXANE + gemcitabine
  • 8% of patients who received ABRAXANE + gemcitabine permanently discontinued ABRAXANE due to peripheral neuropathy

APPROPRIATE DOSE MODIFICATION FOR PERIPHERAL NEUROPATHY

Assessing the severity of peripheral neuropathy is key to determining dose modifications
No recommended for Dose modification of ABRAXANE for peripheral neuropathy: Grade 1 or 2
ABRAXANE Dose modification for peripheral neuropathy: Grade ≥3 ABRAXANE Dose modification for peripheral neuropathy: Grade ≥3
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL